- Home
- STSS vs NRXP Comparison
STSS vs NRXP Comparison
Compare STSS & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STSS | NRXP |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.7M | 62.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | STSS | NRXP |
|---|---|---|
| Price | $1.85 | $1.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | 344.7K | ★ 523.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $847.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.01 | $1.58 |
| 52 Week High | $18.23 | $3.84 |
Technical Indicators
Market Signals| Indicator | STSS | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 48.64 | 46.11 |
| Support Level | $1.65 | $1.65 |
| Resistance Level | $2.04 | $2.79 |
| Average True Range (ATR) | 0.14 | 0.10 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 52.38 | 56.90 |
Price Performance
Historical ComparisonAbout STSS Sharps Technology Inc.
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes designed to eliminate potentially infectious and accidental needlestick injuries.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.